A 12-Week, Multicenter, Safety and Dose-Ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis - Related Studies

A 12-Week, Multicenter, Safety and Dose-Ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis

This study has been completed.

Study NCT00036413. Last updated on November 29, 2007. Information provided by Novartis

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Amyotrophic Lateral Sclerosis

2	Additional conditions recognized in this trial
		Motor Neuron Disease
		Sclerosis

3	More general conditions related to this trial
		Central Nervous System Diseases
		Nervous System Diseases
		Neurodegenerative Diseases
		Neuromuscular Diseases
		Pathologic Processes
		Spinal Cord Diseases

4	Interventions listed in this trial
		TCH346

5	Sponsors listed in this trial
		Novartis